192 related articles for article (PubMed ID: 33022821)
1. Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis.
Haldar D; Janmohamed A; Plant T; Davidson M; Norman H; Russell E; Serevina O; Chung K; Qamar K; Gunson B; Hansen B; Richter A; Trivedi PJ; Hirschfield GM
Liver Int; 2021 Mar; 41(3):535-544. PubMed ID: 33022821
[TBL] [Abstract][Full Text] [Related]
2. Clinical performance of AMA-M2, anti-gp210 and anti-sp100 antibody levels in primary biliary cholangitis: When detected by multiplex bead-based flow fluorescent immunoassay.
Wang Z; Li Y; Ren L; Li Y; Xu T; Li W; Gao W; Sun G; Liu M
Immun Inflamm Dis; 2024 Jan; 12(1):e1161. PubMed ID: 38270327
[TBL] [Abstract][Full Text] [Related]
3. The antinuclear autoantibodies Sp100 and gp210 persist after orthotopic liver transplantation in patients with primary biliary cirrhosis.
Luettig B; Boeker KH; Schoessler W; Will H; Loges S; Schmidt E; Worman HJ; Gershwin ME; Manns MP
J Hepatol; 1998 May; 28(5):824-8. PubMed ID: 9625318
[TBL] [Abstract][Full Text] [Related]
4. [How to understand the clinical significance of autoantibodies in primary biliary cholangitis].
Yan HP; Zhang HP; Chen XX
Zhonghua Gan Zang Bing Za Zhi; 2017 Nov; 25(11):810-815. PubMed ID: 29325273
[TBL] [Abstract][Full Text] [Related]
5. Presence of anti-gp210 or anti-sp100 antibodies in AMA-positive patients may help support a diagnosis of primary biliary cholangitis.
Jaskowski TD; Nandakumar V; Novis CL; Palmer M; Tebo AE
Clin Chim Acta; 2023 Feb; 540():117219. PubMed ID: 36610465
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of antibodies to gp210 among patients with primary biliary cholangitis in Northeast China.
Chen Q; Zhong R; Dong K; Wang Y; Kui Y; Ma B; Wen X; Jin Q
Dig Liver Dis; 2022 Aug; 54(8):1094-1100. PubMed ID: 34789400
[TBL] [Abstract][Full Text] [Related]
7. Role of autoantibodies in the clinical management of primary biliary cholangitis.
Rigopoulou EI; Bogdanos DP
World J Gastroenterol; 2023 Mar; 29(12):1795-1810. PubMed ID: 37032725
[TBL] [Abstract][Full Text] [Related]
8. Anti-gp210-positive primary biliary cholangitis: The dilemma of clinical treatment and emerging mechanisms.
Wang X; Yang Z; Ran Y; Li L; Wang B; Zhou L
Ann Hepatol; 2023; 28(5):101121. PubMed ID: 37302574
[TBL] [Abstract][Full Text] [Related]
9. Anti-gp210 and anti-Sp100 antibodies in primary biliary cholangitis.
Ben Lamine Z; Ben Jazia I; Ben Ahmed M; Ben Slama A; Baccouche A; Slama F; Jemaa A; Ghedira I; Mankaï A
Arab J Gastroenterol; 2021 Dec; 22(4):316-320. PubMed ID: 34090832
[TBL] [Abstract][Full Text] [Related]
10. Novel Anti-Hexokinase 1 Antibodies Are Associated With Poor Prognosis in Patients With Primary Biliary Cholangitis.
Reig A; Norman GL; Garcia M; Shums Z; Ruiz-Gaspà S; Bentow C; Mahler M; Romera MA; Vinas O; Pares A
Am J Gastroenterol; 2020 Oct; 115(10):1634-1641. PubMed ID: 32467507
[TBL] [Abstract][Full Text] [Related]
11. The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210.
Yang F; Yang Y; Wang Q; Wang Z; Miao Q; Xiao X; Wei Y; Bian Z; Sheng L; Chen X; Qiu D; Fang J; Tang R; Gershwin ME; Ma X
Aliment Pharmacol Ther; 2017 Mar; 45(5):733-743. PubMed ID: 28083929
[TBL] [Abstract][Full Text] [Related]
12. Autoimmune Markers in Primary Biliary Cholangitis.
Shah SK; Bowlus CL
Clin Liver Dis; 2024 Feb; 28(1):93-101. PubMed ID: 37945165
[TBL] [Abstract][Full Text] [Related]
13. Autoantibodes to GP210 are a metric for UDCA responses in primary biliary cholangitis.
Wang C; Qin Z; Zhang M; Dai Y; Zhang L; Tian W; Gong Y; Chen S; Yang C; Xu P; Shi X; Zhao W; Timilsina S; Gershwin ME; Chen W; Qiu F; Liu X
J Transl Autoimmun; 2024 Jun; 8():100239. PubMed ID: 38550612
[TBL] [Abstract][Full Text] [Related]
14. High prevalence of primary biliary cirrhosis and disease-associated autoantibodies in Japanese patients with systemic sclerosis.
Imura-Kumada S; Hasegawa M; Matsushita T; Hamaguchi Y; Encabo S; Shums Z; Norman GL; Takehara K; Fujimoto M
Mod Rheumatol; 2012 Nov; 22(6):892-8. PubMed ID: 22327744
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease.
Gatselis NK; Zachou K; Norman GL; Gabeta S; Papamichalis P; Koukoulis GK; Dalekos GN
Autoimmunity; 2013 Nov; 46(7):471-9. PubMed ID: 23777462
[TBL] [Abstract][Full Text] [Related]
16. Antimitochondrial antibody-negative chronic nonsuppurative destructive cholangitis. Atypical primary biliary cirrhosis or autoimmune cholangitis?
Sánchez-Pobre P; Castellano G; Colina F; Dominguez P; Rodriguez S; Canga F; Herruzo JA
J Clin Gastroenterol; 1996 Oct; 23(3):191-8. PubMed ID: 8899500
[TBL] [Abstract][Full Text] [Related]
17. Value of autoantibody analysis in the differential diagnosis of chronic cholestatic liver disease.
Milkiewicz P; Buwaneswaran H; Coltescu C; Shums Z; Norman GL; Heathcote EJ
Clin Gastroenterol Hepatol; 2009 Dec; 7(12):1355-60. PubMed ID: 19631286
[TBL] [Abstract][Full Text] [Related]
18. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis.
Nakamura M; Shimizu-Yoshida Y; Takii Y; Komori A; Yokoyama T; Ueki T; Daikoku M; Yano K; Matsumoto T; Migita K; Yatsuhashi H; Ito M; Masaki N; Adachi H; Watanabe Y; Nakamura Y; Saoshiro T; Sodeyama T; Koga M; Shimoda S; Ishibashi H
J Hepatol; 2005 Mar; 42(3):386-92. PubMed ID: 15710222
[TBL] [Abstract][Full Text] [Related]
19. Correlation between individual autoantibodies and clinical features in primary biliary cholangitis: results of a retrospective longitudinal study.
Dias B; Aguiar A; Morais CI; Nery FG
Eur J Gastroenterol Hepatol; 2023 Jun; 35(6):682-689. PubMed ID: 37116005
[TBL] [Abstract][Full Text] [Related]
20. Antimitochondrial antibody-negative primary biliary cirrhosis: a subset of primary biliary cirrhosis.
Liu B; Shi XH; Zhang FC; Zhang W; Gao LX
Liver Int; 2008 Feb; 28(2):233-9. PubMed ID: 18251980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
